Inventor · disambiguated record
Douglas F. Burdi
Also filed as: BURDI DOUGLAS · BURDI DOUGLAS F
5 granted patents·6 pending applications·13 citations·filing 2003–2020
73Inventor score
Files withSUNOVION PHARMACEUTICALS INC5BLUE OAK PHARMACEUTICALS INC2MILLENNIUM PHARM INC2BURDI DOUGLAS1DAI MINGSHI1
Top patents by PatentIndex Score
11 records- 0187US11491133B2Heteroaryl-isochroman compounds and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2020·Granted Nov 8, 2022·2 cites·57 claims
- 0280US10780074B2Compounds and uses thereofSUNOVION PHARMACEUTICALS INC·Filed 2018·Granted Sep 22, 2020·2 cites·55 claims
- 0372US7491827B2Aryl sulfonamides useful as inhibitors of chemokine receptor activityMILLENNIUM PHARM INC·Filed 2004·Granted Feb 17, 2009·5 cites·32 claims
- 0467US7378525B2CCR8 inhibitorsMILLENNIUM PHARM INC·Filed 2003·Granted May 27, 2008·4 cites·9 claims
- 0556US8063222B2Aryl sulfonamides useful as inhibitors of chemokine receptor activityDAI MINGSHI·Filed 2008·Granted Nov 22, 2011·0 cites·20 claims
- 0651US2023109801A1Compounds and compositions for treating cns disordersBLUE OAK PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0750US2023116114A1Compounds and compositions for treating cns disordersBLUE OAK PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 0834US2016083400A1Tricyclic guanidine derivativeSUNOVION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 0934US2017273985A1Tricyclic derivativeSUNOVION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1033US2012029190A1Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereofBURDI DOUGLAS·Filed 2010·Application pending·0 cites
- 1133US2016083391A1Tricyclic piperazine derivativeSUNOVION PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Douglas F. Burdi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →